Company intelligence / Profile preview

Eupraxia Pharmaceuticals Inc.

Victoria, British Columbia, Canada

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 2b clinical trial (SPRINGBOARD) for EP-104IAR for knee osteoarthritis pain, which met its primary endpoint and three of four secondary endpoints. Currently conducting Phase 1b/2a RESOLVE trial for EP-104GI for eosinophilic esophagitis with positive data from the first six cohorts showing improvements in tissue health and symptom reduction[3][5][6].

Therapeutic areas: GastroenterologyOncologyRheumatology
Modalities: Extended-release drug formulations
Industry: Biotech

Drug pipeline

3 assets

EP-104IAR

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Eupraxia Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eupraxia Pharmaceuticals Inc..

Explore the full profile